
    
      This is a single-center, open-label study, lasting 36 months including an estimated period of
      24 months for the enrollment and max 12 months of follow-up. All patients affected by MPM and
      referred to our Institution eligible for therapeutic pleurodesis and subsequent platinum- and
      pemetrexed-based chemotherapy will be enrolled. In all cases patients will be investigated
      with 11C-Methionine PET/CT and 18F-FDG PET/CT before talc pleurodesis, one week after and at
      the end of three cycles of chemotherapy.

      A minimum number of 20 patients will be considered for the analysis.
    
  